Targeting early events in prostate cancer lineage plasticity
针对前列腺癌谱系可塑性的早期事件
基本信息
- 批准号:10587265
- 负责人:
- 金额:$ 48.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-12-01 至 2027-11-30
- 项目状态:未结题
- 来源:
- 关键词:AffinityAnchorage-Independent GrowthAndrogen ReceptorAndrogensAutomobile DrivingBasal CellBenignBiologyBiopsyCastrationCell LineCell LineageCellsCessation of lifeChIP-seqChromatinClassificationClinicalClinical TrialsDataData SetDevelopmentDiseaseERBB2 geneEndocrineEpithelial CellsEpitheliumEventGene Expression RegulationGenesGenetic TranscriptionGenomic approachGenomicsGrowthIn VitroKnockout MiceLigandsMalignant NeoplasmsMalignant neoplasm of prostateModelingNeurosecretory SystemsOncogenesOncogenicOrganoidsOutcomePathway interactionsPatientsPharmaceutical PreparationsPhenotypePreventionProcessProstateProstate Cancer therapyProstatic NeoplasmsRecurrenceResistanceResistance developmentRoleSpecific qualifier valueStainsStanoloneStressTestingTestosteroneTherapeuticTissuesTumor BiologyTumor Suppressor ProteinsUnited StatesUp-RegulationWarabirateroneaddictionadvanced diseaseadvanced prostate cancerandrogen deprivation therapyandrogen sensitiveantagonistcastration resistant prostate cancercell typeclinical developmentdrug sensitivityeffective therapyefficacy testingenzalutamidegenome-widehormone therapyin vivoinhibitorknock-downmalemigrationnovel therapeutic interventionpatient derived xenograft modelpharmacologicpressurepreventprogramsprostate cancer cellspatiotemporalstandard of carestem cellssynergismtargeted treatmenttherapeutic evaluationtherapeutic targettherapeutically effectivetherapy resistanttranscription factortranscriptome sequencingtreatment strategytumor
项目摘要
PROJECT SUMMARY/ABSTRACT
Prostate cancer is the most common non-cutaneous cancer in males. Prostate cancer cells are dependent on
a transcription factor called the androgen receptor (AR), which is activated by the androgens testosterone and
dihydrotestosterone. Accordingly, an effective treatment for patients with advanced prostate cancer is
androgen deprivation therapy, which blocks the effects of androgens, inhibits the AR, and halts the growth of
prostate cancer cells. Although this form of treatment is very effective for advanced prostate cancer, the stress
of this therapy will eventually lead to the prostate cancer cells developing resistance. In approximately 25-30%
of cases, the stress of prostate cancer therapy will cause the prostate cancer cells to transform into cellular
states where they no longer resemble the original disease. These prostate cancer cells take on features of
alternative cell types through a process called lineage plasticity. These lineage plastic prostate cancers are
very difficult to treat because they do not contain AR and there are no effective therapeutics available.
Additionally, the processes by which standard prostate cancer therapies can cause prostate cancer lineage
plasticity is poorly understood. This proposal seeks to understand the biology of prostate cancer lineage
plasticity and develop new therapeutic strategies to treat, prevent, or reverse this disease stage. Our
preliminary data demonstrates the stem cell transcription factor KLF5 is up-regulated by standard prostate
cancer therapies that inhibit the AR. Up-regulation of KLF5 enhances androgen-independent growth of
prostate cancer cells, as well as migration and colony formation phenotypes. Functionally, the transcriptional
program initiated by up-regulated KLF5 clashes with the transcriptional program activated by the AR. Because
the AR transcriptional program controls prostate cancer cell identity, KLF5 up-regulation breaks down this
identity and promotes very early steps in lineage plasticity of prostate cancer cells. We hypothesize that
targeting this early step in therapy-induced prostate cancer lineage plasticity will block later events that lead to
very aggressive, treatment-resistant manifestations of the disease. We have identified ERBB2 as a focal point
of this tug-of-war between AR and KLF5, and shown that ERBB2 inhibitors can block the oncogenic effects of
KLF5. To advance these findings and identify additional therapeutic vulnerabilities in this pathway, we propose
2 Specific Aims. In Aim 1, we will study induction of KLF5 and lineage plasticity phenotypes in CRPC. In Aim 2,
we will test therapeutic potential of blocking early steps in CRPC lineage plasticity. A successful outcome can
lead to rapid development of clinical trials testing these therapeutic strategies for treatment or prevention of
lineage plastic prostate cancer.
项目总结/摘要
前列腺癌是男性最常见的非皮肤癌。前列腺癌细胞依赖于
一种被称为雄激素受体(AR)的转录因子,由雄激素睾酮激活,
双氢睾酮因此,晚期前列腺癌患者的有效治疗是
雄激素剥夺疗法,阻断雄激素的作用,抑制AR,并停止生长,
前列腺癌细胞虽然这种形式的治疗对晚期前列腺癌非常有效,
这种疗法的效果最终会导致前列腺癌细胞产生抗药性。约25-30%
前列腺癌治疗的压力会导致前列腺癌细胞转化为细胞癌,
在这些州,它们不再与原来的疾病相似。这些前列腺癌细胞呈现出
通过一个叫做谱系可塑性的过程来改变细胞类型。这些谱系可塑性前列腺癌是
非常难以治疗,因为它们不含AR,并且没有有效的治疗方法。
此外,标准前列腺癌疗法可引起前列腺癌谱系的过程
可塑性是知之甚少。这项提案旨在了解前列腺癌谱系的生物学
可塑性和开发新的治疗策略来治疗,预防或逆转这种疾病阶段。我们
初步数据表明,干细胞转录因子KLF 5是上调的标准前列腺
抑制AR的癌症疗法。KLF 5的上调增强了雄激素非依赖性生长,
前列腺癌细胞,以及迁移和集落形成表型。从功能上讲,
由上调的KLF 5启动的程序与由AR激活的转录程序冲突。因为
AR转录程序控制前列腺癌细胞身份,KLF 5上调打破了这一点
身份和促进前列腺癌细胞谱系可塑性的非常早期的步骤。我们假设
靶向治疗诱导的前列腺癌谱系可塑性的这一早期步骤将阻断导致前列腺癌的后期事件。
非常具有攻击性,难以治疗的疾病表现。我们已经确定ERBB 2为焦点
这场AR和KLF 5之间的拉锯战,并表明ERBB 2抑制剂可以阻断AR和KLF 5的致癌作用。
KLF 5。为了推进这些发现并确定该途径中的其他治疗漏洞,我们建议
2具体目标在目的1中,我们将研究CRPC中KLF 5的诱导和谱系可塑性表型。在目标2中,
我们将测试阻断CRPC谱系可塑性的早期步骤的治疗潜力。成功的结果可以
导致临床试验的快速发展,测试这些治疗策略用于治疗或预防
谱系可塑性前列腺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Scott M. Dehm其他文献
Haploinsufficiency of the Maspin tumor suppressor gene leads to hyperplastic lesions in the prostate: Shao LJ, Shi HY, Ayala G, Rowley D, Zhang M, <em>Departments of Molecular and Cellular Biology and Pathology, Baylor College of Medicine, Houston, TX; Department of Molecular Pharmacology and Biological Chemistry, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL</em>
- DOI:
10.1016/j.urolonc.2008.09.007 - 发表时间:
2008-11-01 - 期刊:
- 影响因子:
- 作者:
Scott M. Dehm - 通讯作者:
Scott M. Dehm
CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells
CPSF1 抑制促进了基因间多聚腺苷酸化位点的广泛使用,并损害了前列腺癌细胞中的糖酵解。
- DOI:
10.1016/j.celrep.2024.115211 - 发表时间:
2025-01-28 - 期刊:
- 影响因子:6.900
- 作者:
Kiel T. Tietz;Braedan M. McCluskey;Conor R. Miller;Yingming Li;Sarah A. Munro;Scott M. Dehm - 通讯作者:
Scott M. Dehm
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients
AR 改变可提示转移性去势抵抗性前列腺癌患者循环肿瘤 DNA 的检测
- DOI:
10.1038/s41467-024-54847-1 - 发表时间:
2024-12-11 - 期刊:
- 影响因子:15.700
- 作者:
Todd P. Knutson;Bin Luo;Anna Kobilka;Jacqueline Lyman;Siyuan Guo;Sarah A. Munro;Yingming Li;Rakesh Heer;Luke Gaughan;Michael J. Morris;Himisha Beltran;Charles J. Ryan;Emmanuel S. Antonarakis;Andrew J. Armstrong;Susan Halabi;Scott M. Dehm - 通讯作者:
Scott M. Dehm
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer: Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC, <em>The Prostate Center at Vancouver General Hospital, British Columbia, Canada</em>
- DOI:
10.1016/j.urolonc.2008.09.006 - 发表时间:
2008-11-01 - 期刊:
- 影响因子:
- 作者:
Scott M. Dehm - 通讯作者:
Scott M. Dehm
Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: A novel role of AR mutation for prostate cancer development: Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, Asim M, Roell D, Prade I, Farsetti A, Baniahmad A, <em>Institute of Human Genetics and Anthropology, Jena, Germany</em>
- DOI:
10.1016/j.urolonc.2008.09.008 - 发表时间:
2008-11-01 - 期刊:
- 影响因子:
- 作者:
Scott M. Dehm - 通讯作者:
Scott M. Dehm
Scott M. Dehm的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Scott M. Dehm', 18)}}的其他基金
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
晚期前列腺癌中 Trop-2 的分子调控和表达:确定最佳治疗领域
- 批准号:
10735996 - 财政年份:2023
- 资助金额:
$ 48.68万 - 项目类别:
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer
药理学 Jak2 抑制可克服前列腺癌中的雄激素受体畸变
- 批准号:
10443971 - 财政年份:2022
- 资助金额:
$ 48.68万 - 项目类别:
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer
药理学 Jak2 抑制可克服前列腺癌中的雄激素受体畸变
- 批准号:
10576409 - 财政年份:2022
- 资助金额:
$ 48.68万 - 项目类别:
AR Gene Rearrangements and AR Signaling in Prostate Cancer
前列腺癌中的 AR 基因重排和 AR 信号转导
- 批准号:
9246444 - 财政年份:2013
- 资助金额:
$ 48.68万 - 项目类别:
AR Gene Rearrangements and AR Signaling in Prostate Cancer
前列腺癌中的 AR 基因重排和 AR 信号转导
- 批准号:
8826081 - 财政年份:2013
- 资助金额:
$ 48.68万 - 项目类别:
AR gene rearrangements and AR signaling in prostate cancer
前列腺癌中的 AR 基因重排和 AR 信号传导
- 批准号:
10363701 - 财政年份:2013
- 资助金额:
$ 48.68万 - 项目类别:
AR Gene Rearrangements and AR Signaling in Prostate Cancer
前列腺癌中的 AR 基因重排和 AR 信号转导
- 批准号:
8476830 - 财政年份:2013
- 资助金额:
$ 48.68万 - 项目类别:
AR gene rearrangements and AR signaling in prostate cancer
前列腺癌中的 AR 基因重排和 AR 信号传导
- 批准号:
9912109 - 财政年份:2013
- 资助金额:
$ 48.68万 - 项目类别:
AR Gene Rearrangements and AR Signaling in Prostate Cancer
前列腺癌中的 AR 基因重排和 AR 信号转导
- 批准号:
10656833 - 财政年份:2013
- 资助金额:
$ 48.68万 - 项目类别:
相似海外基金
Role of anchorage-independent growth regulation in tumor progression
不依赖锚定的生长调节在肿瘤进展中的作用
- 批准号:
15K06829 - 财政年份:2015
- 资助金额:
$ 48.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Anchorage-independent growth and EMT relationship in esophageal cancer.
食管癌的锚定非依赖性生长和 EMT 关系。
- 批准号:
23659637 - 财政年份:2011
- 资助金额:
$ 48.68万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Understanding the molecular mechanism required for an anchorage-independent growth of CD133-positive ovarian cancer cells
了解 CD133 阳性卵巢癌细胞非贴壁依赖性生长所需的分子机制
- 批准号:
23800055 - 财政年份:2011
- 资助金额:
$ 48.68万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Functional analysis of a novel signal molecule CDCP1 which regulates anchorage-independent growth in cancer cells
调节癌细胞贴壁依赖性生长的新型信号分子CDCP1的功能分析
- 批准号:
21590350 - 财政年份:2009
- 资助金额:
$ 48.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Pathophysiology of lymphatic stomata in the pathogenesis of cancerous pleural effusion and mechanisms of anchorage-independent growth of cancer
癌性胸腔积液发病机制中淋巴气孔的病理生理学和癌症非锚定依赖性生长机制
- 批准号:
20790993 - 财政年份:2008
- 资助金额:
$ 48.68万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
ANCHORAGE INDEPENDENT GROWTH INDUCED BY CDC42
CDC42 带来的安克雷奇独立增长
- 批准号:
6513557 - 财政年份:2000
- 资助金额:
$ 48.68万 - 项目类别:
ANCHORAGE INDEPENDENT GROWTH INDUCED BY CDC42
CDC42 带来的安克雷奇独立增长
- 批准号:
6633392 - 财政年份:2000
- 资助金额:
$ 48.68万 - 项目类别:
ANCHORAGE INDEPENDENT GROWTH INDUCED BY CDC42
CDC42 带来的安克雷奇独立增长
- 批准号:
6042591 - 财政年份:2000
- 资助金额:
$ 48.68万 - 项目类别:
ANCHORAGE INDEPENDENT GROWTH INDUCED BY CDC42
CDC42 带来的安克雷奇独立增长
- 批准号:
6377153 - 财政年份:2000
- 资助金额:
$ 48.68万 - 项目类别:
ANCHORAGE INDEPENDENT GROWTH INDUCED BY CDC42
CDC42 带来的安克雷奇独立增长
- 批准号:
6771684 - 财政年份:2000
- 资助金额:
$ 48.68万 - 项目类别: